141 related articles for article (PubMed ID: 26835713)
1. Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
He YC; Shen Y; Cao Y; Tang FQ; Tian DF; Huang CF; Tao H; Zhou FL; Zhang B; Song L; He L; Lin LM; Lu FG; Liao DF; Cao D
Cancer Biomark; 2016; 16(1):127-35. PubMed ID: 26835713
[TBL] [Abstract][Full Text] [Related]
2. Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Guo Y; Luo W; Hu Z; Li J; Li X; Cao H; Li J; Wen B; Zhang J; Cheng H; Guo W; Tan T; Luo D
Cell Biosci; 2016; 6():18. PubMed ID: 26949513
[TBL] [Abstract][Full Text] [Related]
3. Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Chung YT; Matkowskyj KA; Li H; Bai H; Zhang W; Tsao MS; Liao J; Yang GY
Mod Pathol; 2012 May; 25(5):758-66. PubMed ID: 22222635
[TBL] [Abstract][Full Text] [Related]
4. AKR1B10 confers resistance to radiotherapy via FFA/TLR4/NF-κB axis in nasopharyngeal carcinoma.
Liu X; Hu Z; Qu J; Li J; Gong K; Wang L; Jiang J; Li X; He R; Duan L; Luo W; Xia C; Luo D
Int J Biol Sci; 2021; 17(3):756-767. PubMed ID: 33767586
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
Han C; Gao L; Zhao L; Sheng Q; Zhang C; An Z; Xia T; Ding Y; Wang J; Bai H; Dou X
Med Sci Monit; 2018 Oct; 24():7414-7423. PubMed ID: 30328412
[TBL] [Abstract][Full Text] [Related]
6. Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
Matkowskyj KA; Bai H; Liao J; Zhang W; Li H; Rao S; Omary R; Yang GY
Hum Pathol; 2014 Apr; 45(4):834-43. PubMed ID: 24656094
[TBL] [Abstract][Full Text] [Related]
7. High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
Ha SY; Song DH; Lee JJ; Lee HW; Cho SY; Park CK
Gut Liver; 2014 Nov; 8(6):648-54. PubMed ID: 25287169
[TBL] [Abstract][Full Text] [Related]
8. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
[TBL] [Abstract][Full Text] [Related]
9. Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Sato S; Genda T; Ichida T; Murata A; Tsuzura H; Narita Y; Kanemitsu Y; Ishikawa S; Kikuchi T; Mori M; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
J Gastroenterol Hepatol; 2016 Jul; 31(7):1315-22. PubMed ID: 26758591
[TBL] [Abstract][Full Text] [Related]
10. Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours.
Heringlake S; Hofdmann M; Fiebeler A; Manns MP; Schmiegel W; Tannapfel A
J Hepatol; 2010 Feb; 52(2):220-7. PubMed ID: 20036025
[TBL] [Abstract][Full Text] [Related]
11. Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Yoshitake H; Takahashi M; Ishikawa H; Nojima M; Iwanari H; Watanabe A; Aburatani H; Yoshida K; Ishi K; Takamori K; Ogawa H; Hamakubo T; Kodama T; Araki Y
Int J Gynecol Cancer; 2007; 17(6):1300-6. PubMed ID: 17425679
[TBL] [Abstract][Full Text] [Related]
12. AKR1B10 expression by immunohistochemistry in surgical resections and fine needle aspiration cytology material in patients with cystic pancreatic lesions; potential for improved nonoperative diagnosis.
Connor JP; Esbona K; Matkowskyj KA
Hum Pathol; 2017 Dec; 70():77-83. PubMed ID: 29079172
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of CDK5 infers poor outcomes for nasopharyngeal carcinoma patients.
Zhang X; Zhong T; Dang Y; Li Z; Li P; Chen G
Int J Clin Exp Pathol; 2015; 8(7):8066-74. PubMed ID: 26339373
[TBL] [Abstract][Full Text] [Related]
14. Nuclear expression of CDK4 correlates with disease progression and poor prognosis in human nasopharyngeal carcinoma.
Jiang Q; Mai C; Yang H; Wu Q; Hua S; Yan C; Long Y; Zhang Y; Long X; Fang W; Liu Z
Histopathology; 2014 Apr; 64(5):722-30. PubMed ID: 24168228
[TBL] [Abstract][Full Text] [Related]
15. High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma.
Xu Y; Zheng Z; Gao Y; Duan S; Chen C; Rong J; Wang K; Yun M; Weng H; Ye S; Zhang J
Sci Rep; 2017 Apr; 7(1):745. PubMed ID: 28389646
[TBL] [Abstract][Full Text] [Related]
16. Loss of cytoplasmic KLF4 expression is correlated with the progression and poor prognosis of nasopharyngeal carcinoma.
Liu Z; Yang H; Luo W; Jiang Q; Mai C; Chen Y; Zhen Y; Yu X; Long X; Fang W
Histopathology; 2013 Sep; 63(3):362-70. PubMed ID: 23758499
[TBL] [Abstract][Full Text] [Related]
17. STAR and AKR1B10 are down-regulated in high-grade endometrial cancer.
Sinreih M; Štupar S; Čemažar L; Verdenik I; Frković Grazio S; Smrkolj Š; Rižner TL
J Steroid Biochem Mol Biol; 2017 Jul; 171():43-53. PubMed ID: 28232277
[TBL] [Abstract][Full Text] [Related]
18. Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma.
Ko HH; Cheng SL; Lee JJ; Chen HM; Kuo MY; Cheng SJ
Head Neck; 2017 Jul; 39(7):1327-1332. PubMed ID: 28301069
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients.
Fang CY; Lin YH; Chen CL
J Oral Pathol Med; 2019 Sep; 48(8):712-719. PubMed ID: 31237374
[TBL] [Abstract][Full Text] [Related]
20. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
Wang YY; Qi LN; Zhong JH; Qin HG; Ye JZ; Lu SD; Ma L; Xiang BD; Li LQ; You XM
Sci Rep; 2017 Feb; 7():42199. PubMed ID: 28181486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
